SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights

FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVE

RVPH

Related stories